Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 13, Issue 5, 2006, Pages 463-467

  Sugita, Hiroki ^a   Hirota, Masahiko ^a   Ichihara, Atsushi ^a   Furuhashi, Satoshi ^a   Kihara, Shinichi ^a   Shimada, Shinya ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Bile duct cancer; Chemo therapy; Cisplatin; CPT 11; Gallbladder cancer; Irinotecan

Indexed keywords

CISPLATIN; FLUOROURACIL; GRANISETRON; IRINOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; CLINICAL PROTOCOL; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GALLBLADDER CANCER; HISTOPATHOLOGY; HUMAN; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER RESECTION; LOW DRUG DOSE; LYMPH NODE METASTASIS; MALE; NAUSEA; PANCREATICODUODENECTOMY; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILIARY TRACT NEOPLASMS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 33749244910     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-006-1098-0     Document Type: Article

References (28)

1. B Glimelius K Hoffman PO Sjoden G Jacobsson H Sellstrom LK Enander 1996 Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 593-600 8879373 1:STN:280:ByiD3szntFE%3D
2. T Ishikawa T Horimi Y Shima T Okabayashi Y Nishioka M Hamada 2003 Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder J Hepatobiliary Pancreat Surg 10 233-8 14605981 10.1007/ s00534-003-0848-5
3. S Okada H Ishii H Nose M Yoshimori T Okusaka K Aoki 1994 A phase II study of cisplatin in patients with biliary tract carcinoma Oncology 51 515-7 7970496 1:STN:280:ByqD28%2Flslc%3D
4. M Ducreux P Rougier A Fandi MC Clavero-Fabri AL Villing F Fassone 1998 Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin Ann Oncol 9 653-6 9681080 1:STN:280:DyaK1czks1Smug%3D%3D 10.1023/A:1008241008379
5. YZ Patt MM Hassan RD Lozano KA Waugh AM Hoque AI Frome 2001 Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer Clin Cancer Res 7 3375-80 11705850 1:CAS:528:DC%2BD3MXptFaju7k%3D
6. J Taieb E Mitry V Boige P Artru J Ezenfis T Lecomte 2002 Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma Ann Oncol 13 1192-6 12181241 1:STN:280:DC%2BD38visVertQ%3D%3D 10.1093/annonc/mdf201
7. PM Sanz-Altamira E O'Reilly KE Stuart L Raeburn C Steger NE Kemeny 2001 A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma Ann Oncol 12 501-4 11398883 1:STN:280:DC%2BD3MzjtFantw%3D%3D 10.1023/A:1011135014895
8. JJ Knox D Hedley A Oza LL Siu GR Pond MJ Moore 2004 Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: A review of the Princess Margaret Hospital experience Ann Oncol 15 770-4 15111345 1:STN:280:DC%2BD2c3htFymtw%3D%3D 10.1093/annonc/mdh172
9. P Bhargava CR Jani DM Savarese JL O'Donnell KE Stuart CM Rocha Lima 2003 Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: Preliminary report Oncology (Huntingt) 17 23-6
10. M Penz GV Kornek M Raderer H Ulrich-Pur W Fiebiger A Lenauer 2001 Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer Ann Oncol 12 183-6 11300321 1:STN:280:DC%2BD3M3gvFansg%3D%3D 10.1023/A:1008352123009
11. M Raderer MH Hejna JB Valencak GV Kornek GS Weinlander E Bareck 1999 Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer Oncology 56 177-80 10202270 1:CAS:528:DyaK1MXisFGhsbg%3D 10.1159/000011961
12. JH Harvey FP Smith PS Schein 1984 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract J Clin Oncol 2 1245-8 6092556 1:STN:280:BiqD3s3otVA%3D
13. T Takada Y Nimura H Katoh T Nagakawa T Nakayama T Matsushiro 1998 Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial Hepatogastroenterology 45 2020-6 9951857 1:CAS:528:DyaK1MXhtFKjsbc%3D
14. M Fukuda K Nishio F Kanzawa H Ogasawara T Ishida H Arioka 1996 Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells Cancer Res 56 789-93 8631015 1:CAS:528:DyaK28XhtVClsb4%3D
15. T Tsunoda H Tanimura T Hotta M Tani M Iwahashi K Ishimoto 2000 In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer J Surg Oncol 73 6-11 10649271 1:CAS:528:DC%2BD3cXhtFaru7k%3D 10.1002/ (SICI)1096-9098(200001)73:1<6::AID-JSO3>3.0.CO;2-Q
16. F Kanzawa F Koizumi Y Koh T Nakamura Y Tatsumi H Fukumoto 2001 In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction Clin Cancer Res 7 202-9 11205910 1:CAS:528:DC%2BD3MXht1Wht70%3D
17. K Shirao Y Shimada H Kondo D Saito T Yamao H Ono 1997 Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer J Clin Oncol 15 921-7 9060529 1:CAS:528:DyaK2sXitFCgs7o%3D
18. C Markham DD Stocken AB Hassan 2003 A phase II irinotecan-cisplatin combination in advanced pancreatic cancer Br J Cancer 89 1860-4 14612893 1:CAS:528:DC%2BD3sXovVersL8%3D 10.1038/sj.bjc.6601377
19. S Kakolyris C Kouroussis J Souglakos S Agelaki K Kalbakis N Vardakis 2001 Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer Lung Cancer 34 Suppl 4 S71-6 11742707 10.1016/S0169-5002(01)00384-1
20. Y Nakanishi K Takayama H Wataya M Izumi T Minami K Takano 2002 Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors Chemotherapy 48 205-10 12218268 1:CAS:528:DC%2BD38XmvFWgtL4%3D 10.1159/000063866
21. LB Saltz D Spriggs LJ Schaaf GK Schwartz D Ilson N Kemeny 1998 Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors J Clin Oncol 16 3858-65 9850031 1:CAS:528:DyaK1MXos1Sq
22. N Boku A Ohtsu Y Shimada K Shirao S Seki H Saito 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319-23 10458249 1:CAS:528:DyaK1MXltVyrtg%3D%3D
23. S Shimada N Hayashi T Marutsuka Y Baba S Yokoyama K Iyama 2002 Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: Report of two cases Surg Today 32 1075-80 12541026 10.1007/s005950200217
24. S Shimada Y Yagi M Kuramoto N Aoki M Ogawa 2003 Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil Oncol Rep 10 687-91 12684644 1:CAS:528:DC%2BD3sXjsVOltL0%3D
25. S Shimada Y Yagi K Shiomori M Kuramoto N Aoki M Ogawa 2002 Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil Oncol Rep 9 783-7 12066209 1:CAS:528:DC%2BD38XltlGrsr0%3D
26. S Tashiro T Imaizumi H Ohkawa A Okada T Katoh Y Kawaharada 2003 Pancreaticobiliary maljunction: Retrospective and nationwide survey in Japan J Hepatobiliary Pancreat Surg 10 345-51 14598134 10.1007/ s00534-002-0741-7
27. L Iyer CD King PF Whitington MD Green SK Roy TR Tephly 1998 Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 101 847-54 9466980 1:CAS:528:DyaK1cXht1Wrtrc%3D
28. E Raymond V Boige S Faivre GJ Sanderink O Rixe L Vernillet 2002 Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction J Clin Oncol 20 4303-12 12409328 1:CAS:528:DC%2BD38Xpt1CjtLg%3D 10.1200/JCO.2002.03.123